反応式
[OH:1][CH:2]1[C:7]([O:10][CH3:11])([O:8][CH3:9])[CH2:6][CH2:5][N:4]([C:12]([O:14][C:15]([CH3:18])([CH3:17])[CH3:16])=[O:13])[CH2:3]1.[H-].[Na+].[CH2:21](Cl)[CH:22]=[CH:23][CH3:24]>CN(C=O)C>[CH2:21]([O:1][CH:2]1[C:7]([O:8][CH3:9])([O:10][CH3:11])[CH2:6][CH2:5][N:4]([C:12]([O:14][C:15]([CH3:18])([CH3:17])[CH3:16])=[O:13])[CH2:3]1)/[CH:22]=[CH:23]/[CH3:24]参加物
5
実験手順
The same operation as in Example (90a) was performed using tert-butyl 3-hydroxy-4,4-dimethoxypiperidine-1-carboxylate (5.2 g, 20 mmol), sodium hydride (55% content, 1.31 g, 30 mmol), crotyl chloride (3.63 g, 40 mmol) and DMF (50 mL). The residue was purified by column chromatography (elution solvent: hexane/ethyl acetate=10/1, 4/1, 2/1) to obtain 5.05 g of the title compound as a colorless oily substance (80%).
後処理
- customThe residue was purified by column chromatography (elution solvent: hexane/ethyl acetate=10/1, 4/1, 2/1)
出典と根拠
- ORDレコード
- ord-2e2e4c5beff2404d84b6ef85bbffd421
- 出典データセット
- uspto-grants-2013_09
- 特許番号
- US08536197B2
関連ノート
読み込み中…